Corinne Le Goff is recorded as Board Member and CEO at Imunon, Inc. (IMNN) since July 18, 2022. Imunon, Inc. reported in an 8-K filed March 12, 2024 that Corinne Le Goff resigned as Board of Directors, effective March 15, 2024. Imunon, Inc. reported in an 8-K filed March 12, 2024 that Corinne Le Goff resigned as President and Chief Executive Officer, effective March 15, 2024. Imunon, Inc. reported in an 8-K filed July 19, 2022 that Corinne Le Goff was appointed director, effective July 18, 2022. Equibles holds 4 filed executive changes naming Corinne Le Goff; each is listed under recent activity with its source filing. The proxy statement of Imunon, Inc. reports total compensation of $148,869 for Corinne Le Goff in fiscal 2024, including a base salary of $148,869. Disclosed compensation is on record for 4 fiscal years. Corinne Le Goff has spoken on 8 earnings calls and 1 other investor event across 2 companies, most recently for Viatris Inc on August 6, 2026. Those appearances were for Imunon, Inc. (IMNN) and Viatris Inc (VTRS). Imunon, Inc. is classified in the Biotechnology industry within the Healthcare sector. Viatris Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Imunon, Inc. includes Michael Tardugno (CEO and Chairman), Stacy Lindborg (CEO and Board Member), Stacy R. Lindborg (CEO and Board Member) and 7 others.
“On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the "Board") of Imunon, Inc. (the "Company") of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.”
Imunon, Inc. Form 8-K, filed March 12, 2024
· Read the filing
“On March 6, 2024, Dr. Corinne Le Goff, Pharm.D., informed the Board of Directors (the "Board") of Imunon, Inc. (the "Company") of her resignation from her position as President and Chief Executive Officer of the Company and from the Board, effective as of March 15, 2024.”
Imunon, Inc. Form 8-K, filed March 12, 2024
· Read the filing
Corinne Le Goff on recent calls
“Just to say that, again, we remain very optimistic about Meloxicam. We're expecting this at the end of the year. So, of course, we'll wait for the label to be available to finalize our pricing strategy and value proposition.”
“I was hoping you wouldn't say the years, but good morning, everyone. Today, I want to do three things. I will talk about the strength and the durability of our best business of generics and established brands.”
“To add that we are very excited also about the launch of our branded new products. We mentioned them already in Japan, it's Exergad, a bit recently at the very end of the year for Japan, and in the U.S., low-dose estrogen weekly contraceptive patch.”
“Joining me today is Jeffrey Church, our Chief Financial Officer. In addition, Dr. Khursheed Anwer, our Chief Science Officer, will be available during the Q&A session at the end of our prepared remarks.”
FormerChief Commercial Officer Mr. Meline was hired by the Company on June 8, 2020 and was not an NEO for 2019. Ms. Klinger was hired by the Company on June 1, 2021 and was not an NEO for 2019 or 2020. Dr. Le Goff was hired by the Company on January 19, 2021 and was not an NEO for 2019 or 2020. Dr. Le Goff left the Company on December 17, 2021 but remained a consultant through February 3, 2022. Under her Consulting Agreement, Dr. Le Goff remained eligible for the first tranche of her new hire equity awards (equivalent to 25%); all other tranches were forfeited.
